pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili Italia clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Istituto Gentili Italia projects
3 ClinicalTrials.gov programs sponsored by Istituto Gentili Italia.
Istituto Gentili Italia has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IRST100.39
Istituto Gentili S.r.l.
Mesothelioma
1 trial -
PTC:VS-TC
Istituto Gentili S.r.l.
Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
1 trial -
REGOMA-2
Istituto Gentili S.r.l.
MGMT-Methylated, IDH wild-type glioblastoma
1 trial
Frequently asked questions
How many clinical projects does Istituto Gentili Italia have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.